Clinical study on the treatment of diabetic nephropathy with polyethylene glycol loxenatide

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070919

Enrollment

Unknown

Registered

2023-04-26

Start date

2023-04-30

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy

Interventions

Experimental group:Polyethlene glycol loxenatide

Control group:SGLT-2 inhibitor

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Sign informed consent; 2.Aged 18 years or older and clinically diagnosed type 2 diabetes; 3.7.0%=HbA1c=10.0%; 4.30ml/min/1.73?=eGFR<90ml/min/1.73?; 5.30mg/g<URCR=5000mg/g; 6.Agree to use contraception during the intervention.

Exclusion criteria

Exclusion criteria: 1.Patients with diabetic ketoaciyanzdosis or type 1 diabetes. 2.Patients with serious cardiovascular and cerebrovascular diseases and liver diseases; 3.Kidney transplant patients or patients with dialysis treatment; 4.Allergic or intolerant to GLP-1RA; 5.Use GLP-1RA or SGLT2i within 12 weeks before enrollment; 6.Severe gastrointestinal diseases; 7.History of pancreatitis.

Design outcomes

Primary

Measure	Time frame
UACR;	—

Secondary

Measure	Time frame
Urine A/C;24-hour urine protein quantification;eGFR;HbA1c;	—

Countries

China

Contacts

Public ContactYing Liu

Sunshine Union Hospital

175198989@qq.com+86 18264621181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026